Pfizer’s etrasimod aims to differentiate UC market with strong safety profile

Pfizer’s etrasimod aims to differentiate UC market with strong safety profile

Source: 
Clinical Trials Arena
snippet: 

The market for ulcerative colitis (UC) is filled with various treatment options, and the pipeline is relatively strong. The variety of drug classes currently available for the treatment of UC across the eight major markets (8MM: the US, France, Germany, Italy, Spain, the UK, Japan, and Canada) includes 5-amino salicylates (ASAs), steroids, immunomodulators, anti-tumour necrosis factor (anti-TNF) therapies, anti-interleukin therapies, anti-integrin therapies, Janus kinase (JAK) inhibitors, and sphingosine 1-phosphate (S1P) receptor modulators. A notable agent in the late-stage UC pipeline is Pfizer’s etrasimod, a once-daily oral S1P receptor modulator.